Skip to main content

Advertisement

ADVERTISEMENT

Low-grade Upper Tract Urothelial Cancer News

News
10/20/2022
Study authors evaluated clinical guideline adherence in the management of upper tract urothelial carcinoma.
Study authors evaluated clinical guideline adherence in the management of upper tract urothelial carcinoma.
Study authors evaluated clinical...
10/20/2022
Integrated Healthcare Executive
News
10/12/2022
Through a preoperative questionnaire survey, researchers analyzed the water drinking habits of patients with upper tract urothelial carcinoma and the connection to their pathological characteristics.
Through a preoperative questionnaire survey, researchers analyzed the water drinking habits of patients with upper tract urothelial carcinoma and the connection to their pathological characteristics.
Through a preoperative...
10/12/2022
Veterans Health Today
News
10/03/2022
“The addition of mitomycin C to the coating of silk fibroin stents could be an attractive approach for intracavitary instillation in the upper urinary tract,” concluded researchers, noting that more research is needed.
“The addition of mitomycin C to the coating of silk fibroin stents could be an attractive approach for intracavitary instillation in the upper urinary tract,” concluded researchers, noting that more research is needed.
“The addition of mitomycin C to...
10/03/2022
First Report Managed Care

Advertisement

News
09/20/2022
Upper tract urothelial carcinoma is the third most common cancer associated with Lynch syndrome; however, there is not an established guideline for identifying at patients with UTUC who are at risk of carrying germline mutations.
Upper tract urothelial carcinoma is the third most common cancer associated with Lynch syndrome; however, there is not an established guideline for identifying at patients with UTUC who are at risk of carrying germline mutations.
Upper tract urothelial carcinoma...
09/20/2022
Integrated Healthcare Executive
News
08/19/2022
Data demonstrates finding alternatives to kidney removal among patients with low-grade upper tract urothelial cancer is key to improving patient quality of life.
Data demonstrates finding alternatives to kidney removal among patients with low-grade upper tract urothelial cancer is key to improving patient quality of life.
Data demonstrates finding...
08/19/2022
Integrated Healthcare Executive
News
08/18/2022
“Our findings support endoscopic management for low-grade upper tract urothelial carcinoma as a valid option from oncological aspects but highlight the associated costs,” wrote researchers.
“Our findings support endoscopic management for low-grade upper tract urothelial carcinoma as a valid option from oncological aspects but highlight the associated costs,” wrote researchers.
“Our findings support endoscopic...
08/18/2022
Veterans Health Today

Advertisement

News
08/17/2022
Despite being one of the most common types of bladder cancer, urothelial carcinoma presents several challenges to patients due to the diseases’ tendency to expand and spread cells to other parts of the urinary tract, including the kidney.
Despite being one of the most common types of bladder cancer, urothelial carcinoma presents several challenges to patients due to the diseases’ tendency to expand and spread cells to other parts of the urinary tract, including the kidney.
Despite being one of the most...
08/17/2022
First Report Managed Care
News
08/09/2022
Cancer subtype was associated with different rates of complete pathological response in patients with urothelial carcinoma.
Cancer subtype was associated with different rates of complete pathological response in patients with urothelial carcinoma.
Cancer subtype was associated...
08/09/2022
First Report Managed Care
News
04/13/2021
The FDA has granted accelerated approval to sacituzumab govitecan for the treatment of certain adults with locally advanced or metastatic urothelial cancer.
The FDA has granted accelerated approval to sacituzumab govitecan for the treatment of certain adults with locally advanced or metastatic urothelial cancer.
The FDA has granted accelerated...
04/13/2021
Oncology

Advertisement

News
07/01/2020
The FDA approved avelumab for the first-line maintenance treatment of patients with locally advanced metastatic or urothelial carcinoma who have not progressed on first-line platinum-containing chemotherapy.
The FDA approved avelumab for the first-line maintenance treatment of patients with locally advanced metastatic or urothelial carcinoma who have not progressed on first-line platinum-containing chemotherapy.
The FDA approved avelumab for...
07/01/2020
Oncology

Advertisement